发明授权
US08895702B2 Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
有权
开发掩蔽的治疗性抗体以限制脱靶效应; 应用于抗EGFR抗体
- 专利标题: Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
- 专利标题(中): 开发掩蔽的治疗性抗体以限制脱靶效应; 应用于抗EGFR抗体
-
申请号: US13542805申请日: 2012-07-06
-
公开(公告)号: US08895702B2公开(公告)日: 2014-11-25
- 发明人: John C. Williams , Ulrich Rodeck , Joshua M. Donaldson , Csaba Kari
- 申请人: John C. Williams , Ulrich Rodeck , Joshua M. Donaldson , Csaba Kari
- 申请人地址: US CA Duarte US PA Philadelphia
- 专利权人: City of Hope,Thomas Jefferson University
- 当前专利权人: City of Hope,Thomas Jefferson University
- 当前专利权人地址: US CA Duarte US PA Philadelphia
- 代理机构: Perkins Coie LLP
- 代理商 Lara J. Dueppen
- 主分类号: C07K16/28
- IPC分类号: C07K16/28 ; C07K16/00 ; C07K16/30
摘要:
In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mAb heterodimer complex is provided, comprising a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof.